clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИclinvest-18Research ArticleКАЧЕСТВО ЖИЗНИQUALITY OF LIFEСохранить и улучшить QALYRetaining, and Enhancing, the QALYLipscombJosephLipscombJoseph

PhD, 

Atlanta,GA,USA

noemail@neicon.ruDrummondMichaelDrummondMichael

PhD,

York, UK

noemail@neicon.ruFrybackDennisFrybackDennis

PhD,

Madison, WI, USA

noemail@neicon.ruGoldMartheGoldMarthe

MD, MPH,

New York City, NY, USA

noemail@neicon.ruRevickiDennisRevickDennis

PhD,

Bethesda, MD, USA

noemail@neicon.ruВилюмИ. А.VilumI. A.

ассистент, 

Санкт-Петербург

noemail@neicon.ruПлавинскийС. Л.PlavinskiiS. L.

д.м.н., заведующий кафедрой педагогики, философии и права,

Санкт-Петербург

noemail@neicon.ruБелоусовД. Ю.BelousovD. Yu.

генеральный директор,

г. Москва

noemail@neicon.ruDepartment of Health Policy and Management, Rollins School of Public Health, Emory UniversityСоединённые Штаты АмерикиEmory UniversityUnited StatesUniversity of YorkВеликобританияUniversity of YorkUnited KingdomUniversity of WisconsinСоединённые Штаты АмерикиUniversity of WisconsinUnited StatesCity University of New York Medical SchoolСоединённые Штаты АмерикиCity University of New York Medical SchoolUnited StatesUnited BioSource CorpСоединённые Штаты АмерикиUnited BioSource CorpUnited StatesПервый Санкт-Петербургский государственный медицинский университет имени акад. И.П. Павлова, Санкт-Петербург; Санкт-Петербургский государственный университет, Санкт-ПетербургРоссияFirst Pavlov State Medical University of St. Peterburg; National Medical and Surgical Center of the N.I. PirogovRussian FederationСеверо-Западный Государственный Медицинский университет имени И. И. МечниковаРоссияNorth-Western State Medical University named after I.I. MechnikovRussian FederationООО "Центр фармакоэкономических исследований", г. МоскваРоссияLLC "Center for Pharmacoeconomics Research", MoscowRussian Federation201516052018027991Copyright © Lipscomb J., Drummond M., Fryback D., Gold M., Revicki D., Вилюм И.А., Плавинский С.Л., Белоусов Д.Ю., 20182018Lipscomb J., Drummond M., Fryback D., Gold M., Revicki D., Вилюм И.А., Плавинский С.Л., Белоусов Д.Ю.Lipscomb J., Drummond M., Fryback D., Gold M., Revick D., Vilum I.A., Plavinskii S.L., Belousov D.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/18

Среди средств экономического и политического анализа, требующего интегральной оценки исходов, с учетом как количества лет жизни, так и ее качества, широкое применение получил показатель QALY (годы жизни, откорректированные на качество).

.

quality-adjusted life yearshealth-related quality of lifecost-utility analysisoutcome assessmenthealth statusгоды жизниоткорректированные на качествосвязанное со здоровьем качество жизнианализ цена-пользаоценка исходовстатус здоровьяQALYReferencesDrummond M., Sculpher T.G., O’Brien B.S. Methods for the Economic Evaluation of Health Care Programmes (3rd ed.). New York: Oxford University Press, 2005.Drummond M., Sculpher T.G., O’Brien B.S. Methods for the Economic Evaluation of Health Care Programmes (3rd ed.). New York: Oxford University Press, 2005.Gold M., Siegel R., Weinstein M. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.Gold M., Siegel R., Weinstein M. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.National Institute for Health and Clinical Excellence (NICE). Available from: http://www.nice.org.uk [Accessed January 24, 2009].National Institute for Health and Clinical Excellence (NICE). Available from: http://www.nice.org.uk [Accessed January 24, 2009].O’Donnell J., Pham S., Pashos C., Miller D. Health technology assessment: Lessons learned from around the world. Value Health 2009;12(Suppl.) в печати.O’Donnell J., Pham S., Pashos C., Miller D. Health technology assessment: Lessons learned from around the world. Value Health 2009;12(Suppl.) в печати.ISPOR. ISPOR Thirteenth Annual International Meeting Abstracts. Value Health 2008;3:A1-311.ISPOR. ISPOR Thirteenth Annual International Meeting Abstracts. Value Health 2008;3:A1-311.Statistics Canada. Canadian Community Health Survey. September 2000 and Ongoing. Available from: http://www.statcan.gc.ca [Accessed January 24, 2009].Statistics Canada. Canadian Community Health Survey. September 2000 and Ongoing. Available from: http://www.statcan.gc.ca [Accessed January 24, 2009].Fryback D.G., Dunham N.C., Palta M., et al. Norms for six generic health-related quality-of-life indexes from the national health measurement study. Med Care 2007;45:1162-70.Fryback D.G., Dunham N.C., Palta M., et al. Norms for six generic health-related quality-of-life indexes from the national health measurement study. Med Care 2007;45:1162-70.Fryback D.G., Lawrence W.F., Martin P.A., et al. Predicting quality of well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med Decis Making 1997;17:1-9.Fryback D.G., Lawrence W.F., Martin P.A., et al. Predicting quality of well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study. Med Decis Making 1997;17:1-9.Feeny D., Furlong W., Torrance G.W., et al. Multiattribute and single-attribute utility functions for the Health Utilities Index Mark 3 System. Med Care 2002;40:113-28Feeny D., Furlong W., Torrance G.W., et al. Multiattribute and single-attribute utility functions for the Health Utilities Index Mark 3 System. Med Care 2002;40:113-28Brooks R., Rabin R., de Charro F The Measurement and Valuation of Health Status Using EQ-5D: a European Perspective. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2003.Brooks R., Rabin R., de Charro F The Measurement and Valuation of Health Status Using EQ-5D: a European Perspective. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2003.Andresen E.M., Rothenberg B.M., Kaplan R.M. Performance of a self-administered mail version of the Quality of Well-Being (QWB-SA) Questionnaire among older adults. Med Care 1998; 36:1349-60.Andresen E.M., Rothenberg B.M., Kaplan R.M. Performance of a self-administered mail version of the Quality of Well-Being (QWB-SA) Questionnaire among older adults. Med Care 1998; 36:1349-60.Brazier J.E., Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004;42:851-9.Brazier J.E., Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004;42:851-9.Erickson P. Evaluation of a population-based measure of quality of life: the Health and Activity Limitations Index (HALex). Qual Life Res 1998;7:101-14.Erickson P. Evaluation of a population-based measure of quality of life: the Health and Activity Limitations Index (HALex). Qual Life Res 1998;7:101-14.Mehrez A., Gafni A. Quality-adjusted life years, utility theory, and healthy years equivalents. Med Decis Making 1989;9:142-9.Mehrez A., Gafni A. Quality-adjusted life years, utility theory, and healthy years equivalents. Med Decis Making 1989;9:142-9.Nord E. Cost-Value Analysis in Health Care: Making Sense out of QALYs. New York: Oxford University Press, 1999.Nord E. Cost-Value Analysis in Health Care: Making Sense out of QALYs. New York: Oxford University Press, 1999.Ubel P., Nord E., Gold M., et al. Improving value measurement in cost-effectiveness analysis. Med Care 2000;38:892-901.Ubel P., Nord E., Gold M., et al. Improving value measurement in cost-effectiveness analysis. Med Care 2000;38:892-901.Dolan P., Kahneman D. Interpretations of utility and their implications for the valuation of health. Econ J 2008;118:215-34.Dolan P., Kahneman D. Interpretations of utility and their implications for the valuation of health. Econ J 2008;118:215-34.Hausman D.M. Valuing health properly. Health Econ Policy Law 2008;3:79-83.Hausman D.M. Valuing health properly. Health Econ Policy Law 2008;3:79-83.Miller W., Robinson L.A., Lawrence R.S., eds. Valuing Health for Regulatory Cost-Effectiveness Analysis. Washington DC: Institute of Medicine, National Academy Press, 2006.Miller W., Robinson L.A., Lawrence R.S., eds. Valuing Health for Regulatory Cost-Effectiveness Analysis. Washington DC: Institute of Medicine, National Academy Press, 2006.Neumann P.J. Using Cost-Effectiveness Analysis to Improve Health Care. New York: Oxford University Press, 2005.Neumann P.J. Using Cost-Effectiveness Analysis to Improve Health Care. New York: Oxford University Press, 2005.US Food and Drug Administration. Guidance for industry- patient-reported outcome measures: use in medical product development to support labeling claims. 2006. Available from: http:// www.fda.gov/cber/gdlns/prolbl.pdf [Accessed January 24, 2009].US Food and Drug Administration. Guidance for industry- patient-reported outcome measures: use in medical product development to support labeling claims. 2006. Available from: http:// www.fda.gov/cber/gdlns/prolbl.pdf [Accessed January 24, 2009].U.S. Federal Registry. Medicare program: criteria and procedures for extending coverage decisions that relate to health care technology. US Federal Register 1989;54:4302-18.U.S. Federal Registry. Medicare program: criteria and procedures for extending coverage decisions that relate to health care technology. US Federal Register 1989;54:4302-18.Feeny D. The roles of preference-based measures in support of cancer research and policy. In: Lipscomb J., Gotay C.C., Snyder C., eds. Outcomes Assessment in Cancer: Measures, Methods, Applications. Cambridge: Cambridge University Press, 2005.Feeny D. The roles of preference-based measures in support of cancer research and policy. In: Lipscomb J., Gotay C.C., Snyder C., eds. Outcomes Assessment in Cancer: Measures, Methods, Applications. Cambridge: Cambridge University Press, 2005.Brauer C.A., Rosen A.B., Greenberg D., Neumann P.J. Trends in the measurement of health utilities in published cost-utility analyses. Value Health 2006; 9:213-8.Brauer C.A., Rosen A.B., Greenberg D., Neumann P.J. Trends in the measurement of health utilities in published cost-utility analyses. Value Health 2006; 9:213-8.Szende A., Williams A., eds. Measuring Self-Reported Population Health: an International Perspective Based on the EQ-5D. Budapest: Spring Med Publishing, 2004.Szende A., Williams A., eds. Measuring Self-Reported Population Health: an International Perspective Based on the EQ-5D. Budapest: Spring Med Publishing, 2004.Bryan S., Sofaer S., Siegelberg T., Gold M.R. Has the time come for CEA in U.S. Health Care? J Health Econ Policy Law in press.Bryan S., Sofaer S., Siegelberg T., Gold M.R. Has the time come for CEA in U.S. Health Care? J Health Econ Policy Law in press.US Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey (MEPS). Available from: http:// www.meps.ahrq.gov [Accessed January 24, 2009].US Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey (MEPS). Available from: http:// www.meps.ahrq.gov [Accessed January 24, 2009].Sullivan P. W., Ghushchyan V. Mapping the EQ-5D Index from the SF-12: U.S. general population preferences in a nationally representative sample. Med Decis Making 2006;26:401-9.Sullivan P. W., Ghushchyan V. Mapping the EQ-5D Index from the SF-12: U.S. general population preferences in a nationally representative sample. Med Decis Making 2006;26:401-9.Lawrence W.F., Fleishman J.A. Predicting EuroQol EQ-5D preference scores from the SF-12 Health Survey in a nationally representative sample. Med Decis Making 2004;24:160-9.Lawrence W.F., Fleishman J.A. Predicting EuroQol EQ-5D preference scores from the SF-12 Health Survey in a nationally representative sample. Med Decis Making 2004;24:160-9.Franks P., Lubetkin E.I., Gold M.R., et al. Mapping the SF-12 to the EuroQol EQ-5D Index in a national U.S. sample. Med Decis Making 2004;24:247-54.Franks P., Lubetkin E.I., Gold M.R., et al. Mapping the SF-12 to the EuroQol EQ-5D Index in a national U.S. sample. Med Decis Making 2004;24:247-54.Statistics Canada and the US Centers for Disease Control and Prevention. Joint Canada-United States Survey of Health (JCUSH). Available from: http:// www.cdc.gov/nchs/about/major/ nhis/Canada_US.htm [Accessed January 24, 2009].Statistics Canada and the US Centers for Disease Control and Prevention. Joint Canada-United States Survey of Health (JCUSH). Available from: http:// www.cdc.gov/nchs/about/major/ nhis/Canada_US.htm [Accessed January 24, 2009].Statistics Canada. National Population Health Survey. Available at: http://www.statcan.gc.ca/bsolc/olc-cel/olc-cel?lang=eng& catno=82-618-M [Accessed January 24, 2009].Statistics Canada. National Population Health Survey. Available at: http://www.statcan.gc.ca/bsolc/olc-cel/olc-cel?lang=eng& catno=82-618-M [Accessed January 24, 2009].US Centers for Medicare and Medicaid Services. Medicare Health Outcomes Survey. Available from: http://www.cms.hhs.gov/hos/ [Accessed January 24, 2009].US Centers for Medicare and Medicaid Services. Medicare Health Outcomes Survey. Available from: http://www.cms.hhs.gov/hos/ [Accessed January 24, 2009].Kind P., Dolan P., Gudex C., Williams A. Variations in population health: results from a United Kingdom national questionnaire survey. BMJ 1998; 316: 736-41.Kind P., Dolan P., Gudex C., Williams A. Variations in population health: results from a United Kingdom national questionnaire survey. BMJ 1998; 316: 736-41.Shaw J.W., Johnson J.A., Coons S.J. U.S. Valuation of the EQ-5D Health States: development and testing of the D1 valuation model. Medical Care 2005; 43: 203-20.Shaw J.W., Johnson J.A., Coons S.J. U.S. Valuation of the EQ-5D Health States: development and testing of the D1 valuation model. Medical Care 2005; 43: 203-20.Revicki D.A., Kawata A., Harnam N., et al. Predicting EuroQol (EQ-5D) scores from the Patient Reported Outcomes Measurement Information System (PROMIS) global items and domain item banks in a United States representative sample. UnitedBio-Source Corp. working Paper, November 2008.Revicki D.A., Kawata A., Harnam N., et al. Predicting EuroQol (EQ-5D) scores from the Patient Reported Outcomes Measurement Information System (PROMIS) global items and domain item banks in a United States representative sample. UnitedBio-Source Corp. working Paper, November 2008.Ware JE Jr. SF-36® Health Survey Update. Available from: http:// www.sf-36.org/tools/sf36.shtml [Accessed January 24, 2009].Ware JE Jr. SF-36® Health Survey Update. Available from: http:// www.sf-36.org/tools/sf36.shtml [Accessed January 24, 2009].Horsman J., Furlong W., Feeny D., Torrance G. The Health Utilities Index (HUI): concepts, measurement properties, and applications. Health Qual Life Outcomes 2003;1:54-66.Horsman J., Furlong W., Feeny D., Torrance G. The Health Utilities Index (HUI): concepts, measurement properties, and applications. Health Qual Life Outcomes 2003;1:54-66.Maddigan S.L., Feeny D.H., Johnson J.A., for the DOVE Investigators. A comparison of the Health Utilities Indices Mark 2 and Mark 3 in type 2 diabetes. Med Decis Making 2003;23:489- 501.Maddigan S.L., Feeny D.H., Johnson J.A., for the DOVE Investigators. A comparison of the Health Utilities Indices Mark 2 and Mark 3 in type 2 diabetes. Med Decis Making 2003;23:489- 501.Pickard A., Kohlmann T., Janssen M., et al. Evaluating equivalency between response systems: application of the Rasch Model to 3-Level and 5-Level EQ-5D. Med Care 2007;45:812-9.Pickard A., Kohlmann T., Janssen M., et al. Evaluating equivalency between response systems: application of the Rasch Model to 3-Level and 5-Level EQ-5D. Med Care 2007;45:812-9.National Institutes of Health. Patient-reported outcomes measurement information system: dynamic tools to measure health outcomes from the patient perspective. Available from: http:// www.nihpromis.org [Accessed January 24, 2009].National Institutes of Health. Patient-reported outcomes measurement information system: dynamic tools to measure health outcomes from the patient perspective. Available from: http:// www.nihpromis.org [Accessed January 24, 2009].Petrillo J., Cairns J. Converting condition-specific measures into preference-based outcomes for use in economic evaluation. Exp Rev Pharmacoeconom Res 2008;8:453-6.Petrillo J., Cairns J. Converting condition-specific measures into preference-based outcomes for use in economic evaluation. Exp Rev Pharmacoeconom Res 2008;8:453-6.Franks P., Hanmer J., Fryback D.G. Relative disutilities of 47 risk factors and conditions assessed with seven preference-based health status measures in a national U.S. sample: toward consis-tency in cost-effectiveness analysis. Med Care 2006;44:478- 85.Franks P., Hanmer J., Fryback D.G. Relative disutilities of 47 risk factors and conditions assessed with seven preference-based health status measures in a national U.S. sample: toward consis-tency in cost-effectiveness analysis. Med Care 2006;44:478- 85.Janssen M.F., Birnie E., Bonsel G.J. Evaluating the discriminatory power of EQ-5D, HUI2 and HUI3 in a U.S. general population survey using Shannon’s indices. Qual Life Res 2007;16:895- 904.Janssen M.F., Birnie E., Bonsel G.J. Evaluating the discriminatory power of EQ-5D, HUI2 and HUI3 in a U.S. general population survey using Shannon’s indices. Qual Life Res 2007;16:895- 904.Stevens K., McCabe C., Brazier J., Roberts J. Multi-attribute utility functions or statistical inference models: a comparison of health state valuation models using the HUI2 health state classification system. J Health Econ 2006;26:992-1002.Stevens K., McCabe C., Brazier J., Roberts J. Multi-attribute utility functions or statistical inference models: a comparison of health state valuation models using the HUI2 health state classification system. J Health Econ 2006;26:992-1002.Fryback D., Palta M., Cherepanov D., et al. for the Health Measurement Research Group. Cross-walks among five self-reported summary health utility indexes: progress and prospects. Presented at the Annual Meeting of the Society for Medical Making, Pittsburgh, PA, Oct 24, 2007.Fryback D., Palta M., Cherepanov D., et al. for the Health Measurement Research Group. Cross-walks among five self-reported summary health utility indexes: progress and prospects. Presented at the Annual Meeting of the Society for Medical Making, Pittsburgh, PA, Oct 24, 2007.Scientific Advisory Committee for the Medical Outcomes Trust (Lohr K, et al.) Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002;11:193- 205.Scientific Advisory Committee for the Medical Outcomes Trust (Lohr K, et al.) Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002;11:193- 205.Lipscomb J., Snyder C.F., Gotay C. Cancer outcomes measurement through the lens of the medical outcomes trust framework. Qual Life Res 2007;16:143-64.Lipscomb J., Snyder C.F., Gotay C. Cancer outcomes measurement through the lens of the medical outcomes trust framework. Qual Life Res 2007;16:143-64.Salomon J.A., Murray C.J. A multi-method approach to measuring health-state valuations. Health Econ 2006;13:281-90.Salomon J.A., Murray C.J. A multi-method approach to measuring health-state valuations. Health Econ 2006;13:281-90.Lipscomb J. Time preference for health in cost-effectiveness analysis. Med Care 1989;27:S233-53.Lipscomb J. Time preference for health in cost-effectiveness analysis. Med Care 1989;27:S233-53.Nord E., Pinto J.L., Richardson J., et al. Societal concerns for fairness in numerical valuations of health programmes. Health Econ 1999;8:25-39.Nord E., Pinto J.L., Richardson J., et al. Societal concerns for fairness in numerical valuations of health programmes. Health Econ 1999;8:25-39.Bleichrodt H., Doctor J., Stolk E. A nonparametric elicitation of the equity-efficiency trade-off in cost-utility analysis. J Health Econ 2005;24:655-78.Bleichrodt H., Doctor J., Stolk E. A nonparametric elicitation of the equity-efficiency trade-off in cost-utility analysis. J Health Econ 2005;24:655-78.Wagstaff A. QALYs and the equity-efficiency trade-off. J Health Econ 1991;10:21-41.Wagstaff A. QALYs and the equity-efficiency trade-off. J Health Econ 1991;10:21-41.Johannesson M. Should we aggregate relative or absolute changes in QALYs? Health Econ 2001;10:573-7.Johannesson M. Should we aggregate relative or absolute changes in QALYs? Health Econ 2001;10:573-7.Epstein D.M., Chalabi Z., Claxton K., Sculpher M. Efficiency, equity, and budgetary priorities. Med Decis Making 2007;27: 128-37.Epstein D.M., Chalabi Z., Claxton K., Sculpher M. Efficiency, equity, and budgetary priorities. Med Decis Making 2007;27: 128-37.Stinnett A.A., Paltiel A.D. Mathematical programming for the efficient allocation of health care resources. J Health Econ 1996;15: 641-53Stinnett A.A., Paltiel A.D. Mathematical programming for the efficient allocation of health care resources. J Health Econ 1996;15: 641-53Chen M.M., Bush J.W. Maximizing health system output with political and administrative constraints using mathematical programming. Inquiry 1977;13:215-27.Chen M.M., Bush J.W. Maximizing health system output with political and administrative constraints using mathematical programming. Inquiry 1977;13:215-27.NICE Citizens Council. NICE Citizens Council report: ultra orphan drugs. London, November 2004. Available from: http:// www.nice.org.uk/ [Accessed January 24, 2009]. [Alternatively or together, cite: Culyer AJ. NICE’s Use of Cost-Effectiveness as an Exemplar of a Deliberative Process. Health Econ Policy Law 2006;1:299-318. and/or a critique of the process.]. 59 Gold MR, Sofaer S, Siegelberg T. Medicare and cost-effectiveness analysis: time to ask the taxpayer. Health Aff (Millwood) 2007;26:1399-406NICE Citizens Council. NICE Citizens Council report: ultra orphan drugs. London, November 2004. Available from: http:// www.nice.org.uk/ [Accessed January 24, 2009]. [Alternatively or together, cite: Culyer AJ. NICE’s Use of Cost-Effectiveness as an Exemplar of a Deliberative Process. Health Econ Policy Law 2006;1:299-318. and/or a critique of the process.]. 59 Gold MR, Sofaer S, Siegelberg T. Medicare and cost-effectiveness analysis: time to ask the taxpayer. Health Aff (Millwood) 2007;26:1399-406

The authors declare that there are no conflicts of interest present.